ストックスクリーナーアプリを入手
2.53
2.32%
-0.06
前日終値:
$2.59
開ける：
$2.59
24時間の取引高:
756.77K
Relative Volume:
0.99
時価総額：
$230.20M
収益：
$114.70K
当期純損益:
$-26.49M
株価収益率:
-1.0257
EPS:
-2.4665
ネットキャッシュフロー:
$-53.17M
1週間 パフォーマンス:
-15.10%
1か月 パフォーマンス:
-25.37%
6か月 パフォーマンス:
-35.46%
1年 パフォーマンス:
+16.59%
1日の値動き範囲:
$2.47
$2.63
1週間の範囲:
$2.45
$3.00
52週間の値動き範囲:
$2.10
$5.15
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Compare SABS vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
2.53 | 230.20M | 114.70K | -26.49M | -53.17M | -2.4665 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-06-24 | 開始されました | Barclays | Overweight |
| 2026-05-22 | 開始されました | Citigroup | Buy |
| 2026-05-20 | 開始されました | Jefferies | Buy |
| 2026-04-02 | 開始されました | Rodman & Renshaw | Buy |
| 2025-12-19 | 開始されました | Guggenheim | Buy |
| 2025-09-17 | 開始されました | Leerink Partners | Outperform |
| 2025-05-14 | 再開されました | H.C. Wainwright | Buy |
| 2024-10-09 | 開始されました | Craig Hallum | Buy |
| 2024-08-28 | 開始されました | Oppenheimer | Outperform |
| 2021-11-05 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Sab Biotherapeutics Inc (SABS) 最新ニュース
SAB Biotherapeutics Warrant (SABSW) Trades Flat at $0.01 as Directional Signals Remain ElusiveProtective Put - siam.in
SAB Biotherapeutics Warrant (SABSW) Trades Flat at $0.01 as Directional Signals Remain ElusiveSupply Zone - https://www.dars.gov.et/
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes - Yahoo Finance
Tax withholding trims SAB Biotherapeutics (SABS) CMO stake - Stock Titan
SAB BIO at Citi summit: trial progress and a bigger t1d bet By Investing.com - Investing.com South Africa
SAB BIO at Citi summit: trial progress and a bigger t1d bet - Investing.com India
SAB BIO at Citi summit: trial progress and a bigger t1d bet - Investing.com UK
SAB BIO to Participate in Upcoming Investor Conferences - GlobeNewswire
SAB BIO to Participate in Upcoming Investor Conferences - Yahoo Finance
SAB Biotherapeutics Inc. (SABS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
SAB Biotherapeutics Inc. Warrant (SABSW) Key Financial Ratios – Valuation, Profitability & More - Value Research
SAB (SABSW) Market: Ends Higher by 13.58% at $0.03 in the Current Update; Range Check - vinanet.vn
SAB (SABSW) Session: Moves 7.02% Down to $0.03 at the Close; Boundary Watch - vinanet.vn
SAB (SABS) Today: Posts a 2.16% Gain to $3.78 in the Current Update; Price Setup: the Current Price Sits Inside the Supplied Technical Range in the Latest SessionLiquidity Sweep - vinanet.vn
SAB (SABS) Today: Posts a 2.16% Gain to $3.78 in the Current Update; Price Setup: the Current Price Sits Inside the Supplied Technical Range in the Latest SessionCash Secured Put - vinanet.vn
SAB (SABSW) Latest: Falls 14.29% to $0.02 in the Current Update; Level Watch - vinanet.vn
There are notable gap-ups and gap-downs in today's session. - ChartMill
Price to earnings forward of SAB Biotherapeutics, Inc. – BOATS:SABSW - TradingView
Balyasny Asset Management L.P. Expands Stake in SAB Biotherapeutics Inc (SABS) - GuruFocus
SAB (SABS) Earnings Update: EPS Prints Above Forecast in the Current Update; Market Move: Shares Move Lower 0.26% in the Latest SessionEPS Miss Report - dars.gov.et
SAB (SABS) Earnings Update: EPS Prints Above Forecast in the Current Update; Market Move: Shares Move Lower 0.26% in the Latest SessionROE Trend Analysis - vinanet.vn
SAB Biotherapeutics (SABS) Slips 1.33% to $3.70 as Support Level Comes into FocusCash Flow Strong Stocks - vinanet.vn
SAB Biotherapeutics (SABS) Slips 1.33% to $3.70 as Support Level Comes into FocusRevenue Growth Stocks - dars.gov.et
Perceptive Advisors discloses 7.3% SAB Biotherapeutics (SABS) stake via Master Fund - Stock Titan
Caligan Partners (SABS) discloses 7.97M SAB Biotherapeutics shares in amended 13G - Stock Titan
Commodore Capital discloses 8.95M-share position in SAB Biotherapeutics (SABS) - Stock Titan
Vivo funds (SABS) report capped 9.99% stakes via preferred stock and warrants - Stock Titan
Woodline Partners (SABS) discloses 5.46M-share beneficial stake in SAB Biotherapeutics - Stock Titan
Balyasny Asset Management (SABS) discloses 7.2M-share SAB Biotherapeutics position capped at 9.99% - Stock Titan
Adage discloses 8.38% SAB Biotherapeutics (SABS) ownership in Schedule 13G - Stock Titan
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
SABS Q2 2026 Earnings: Narrower-than-Expected Loss, Yet Stock SlipsROIC Trend Report - dars.gov.et
RA Capital group discloses 9.9% SAB Biotherapeutics (SABS) stake capped by ownership blockers - Stock Titan
What is HC Wainwright's Estimate for SABS Q3 Earnings? - MarketBeat
Q3 EPS Estimate for SAB Biotherapeutics Boosted by Analyst - MarketBeat
SAB Biotherapeutics (NASDAQ:SABS) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat
H.C. Wainwright Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
SAB Biotherapeutics Q2 Earnings Call Highlights - MarketBeat
SAB Biotherapeutics Q2 Earnings Call Highlights - Yahoo Finance
SABS FY2030 EPS Boosted by Brookline Capital Markets - marketbeat.com
SAB Biotherapeutics (SABS) Rises 1.43% to $3.9 — Key Resistance at $4.09 in FocusTriple Bottom - vinanet.vn
SAB Biotherapeutics (NASDAQ:SABS) Posts Earnings Results, Hits Estimates - MarketBeat
SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ... - Yahoo Finance
Earnings call transcript: SAB Bio posts wider Q2 2026 loss as trial momentum builds - Investing.com Nigeria
SAB Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
SAB Biotherapeutics, Inc. Q2 2026: Net loss $(22.5M), EPS $(0.28) — 10-Q Summary - TradingView
SAB Biotherapeutics (NASDAQ: SABS) posts Q2 loss after March 2026 stock offering - Stock Titan
SAB BIO Reports Q2 2026 Results, Expands SAB-142 Type 1 Diabetes Trials and Secures Breakthrough T1D Grant for PRISE-hATG Study - Quiver Quantitative
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights - The Manila Times
Press Release: SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights - Moomoo
Sab Biotherapeutics Inc (SABS) 財務データ
収益
当期純利益
現金流量
EPS
Sab Biotherapeutics Inc (SABS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sessa Capital (Master), L.P. | Director |
Sep 29 '25 |
Option Exercise |
1.75 |
1,740,000 |
3,045,000 |
2,198,457 |
4.22%
大文字化:
|
ボリューム (24 時間):